CHMA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CHMA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chiasma's interest expense for the three months ended in Mar. 2021 was $ -12.46 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2021 was $-18.33 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chiasma's Operating Income for the three months ended in Mar. 2021 was $ -18.04 Mil. Chiasma's Interest Expense for the three months ended in Mar. 2021 was $ -12.46 Mil. Chiasma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Chiasma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiasma Annual Data | |||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||
Interest Expense | Get a 7-Day Free Trial | -0.26 | -0.13 | - | - | -5.87 |
Chiasma Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Interest Expense | Get a 7-Day Free Trial | - | -0.91 | -2.13 | -2.84 | -12.46 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chiasma (NAS:CHMA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Chiasma's Interest Expense for the three months ended in Mar. 2021 was $-12.46 Mil. Its Operating Income for the three months ended in Mar. 2021 was $-18.04 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2021 was $0.00 Mil.
Chiasma's Interest Coverage for the quarter that ended in Mar. 2021 is calculated as
Chiasma did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Roni Mamluk | director | CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459 |
David M Stack | director | THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Raj Kannan | director, officer: Chief Executive Officer | C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451 |
John F Thero | director | C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921 |
Bard Geesaman | director | C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 |
Todd Foley | director | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
John A Scarlett | director | C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025 |
Scott Minick | director | C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139 |
Anand Varadan | officer: EVP, Chief Commerical Officer | C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459 |
Lee Giguere | officer: General Counsel | C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451 |
William Ludlam | officer: See Remarks | C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451 |
Drew Enamait | officer: VP, Fin & Admin, PAO | C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451 |
Mark J. Fitzpatrick | officer: President | 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142 |
James R Tobin | director | C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421 |
Ansbert Gadicke | director | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Marketwired Marketwired • 05-20-2021
By PRNewswire PRNewswire • 05-08-2021
By PRNewswire PRNewswire • 05-20-2021
By PRNewswire PRNewswire • 05-12-2021
By PRNewswire PRNewswire • 05-27-2021
By Business Wire Business Wire • 05-05-2021
By Marketwired Marketwired • 01-19-2021
By Marketwired Marketwired • 03-10-2021
By Marketwired Marketwired • 04-29-2021
By PRNewswire PRNewswire • 05-19-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.